Selective Serotonin Reuptake Inhibitors (Ssri) Interactions

Co-administration with bivalirudin associated with increased risk of major bleeding events in patients undergoing PCI/PTCA.

Source: NLP:bivalirudin

Concomitant use may increase the risk of bleeding. Avoid concomitant use when possible and monitor closely for bleeding.

Source: NLP:caplacizumab

Postmarketing cases of serotonin syndrome reported during combined use. Careful observation advised, particularly during treatment initiation or dose increases.

Source: NLP:cyclobenzaprine hydrochloride

Concomitant use increases risk of serotonin syndrome. Initiate with lower doses and monitor for signs and symptoms.

Source: NLP:dextroamphetamine sulfate

SSRIs with diclofenac potentiate bleeding risk more than NSAID alone. Monitor for signs of bleeding.

Source: NLP:diclofenac potassium, film coated

Concomitant use potentiates bleeding risk more than NSAID alone. Monitor for signs of bleeding.

Source: NLP:diclofenac sodium

Coadministration increases the risk of bleeding.

Source: NLP:eptifibatide

Concomitant use may result in serotonin syndrome including altered mental status, autonomic instability, and neuromuscular symptoms.

Source: NLP:granisetron hydrochloride

Concomitant use may result in serotonin syndrome. Frequently evaluate patient during treatment initiation and dose adjustment.

Source: NLP:hydromorphone hydrochloride

SSRIs with ibuprofen potentiate bleeding risk more than NSAID alone due to interference with serotonin reuptake.

Source: NLP:ibuprofen and famotidine

Concomitant use with SSRIs and NSAIDs potentiates the risk of bleeding more than NSAID alone.

Source: NLP:indomethacin

Concomitant use has resulted in serotonin syndrome.

Source: NLP:levorphanol tartrate

Concomitant administration can precipitate serotonin syndrome. Monitor for signs and symptoms, particularly during lithium initiation.

Source: NLP:lithium carbonate

Concomitant use potentiates risk of bleeding more than NSAID alone due to serotonin reuptake interference affecting platelet hemostasis.

Source: NLP:mefenamic acid

Concomitant use may result in serotonin syndrome. Carefully observe patient during treatment initiation and dosage modification; discontinue metaxalone if serotonin syndrome occurs.

Source: NLP:metaxalone

Concomitant use may result in serotonin syndrome with serious CNS reactions, potentially fatal.

Source: NLP:methylene blue

Concomitant use can result in serotonin syndrome. Requires frequent patient evaluation, particularly during initiation and dose adjustment.

Source: NLP:morphine sulfate

Concomitant use may result in serotonin syndrome. Carefully observe patient during treatment initiation and dose adjustment.

Source: NLP:nalbuphine hydrochloride

SSRIs with naproxen potentiate risk of bleeding more than NSAID alone due to interference with serotonin reuptake and platelet hemostasis.

Source: NLP:naproxen

Concomitant use with naproxen potentiates bleeding risk more than NSAID alone by interfering with serotonin reuptake important for hemostasis.

Source: NLP:naproxen and esomeprazole magnesium

Concomitant use potentiates bleeding risk more than NSAID alone due to serotonin reuptake interference.

Source: NLP:naproxen sodium

Concomitant use may cause serotonin syndrome including altered mental status, autonomic instability, and neuromuscular symptoms. Monitor for emergence of serotonin syndrome.

Source: NLP:ondansetron

Concomitant use may cause serotonin syndrome including altered mental status, autonomic instability, and neuromuscular symptoms. Monitor for emergence of serotonin syndrome; discontinue ondansetron if symptoms occur.

Source: NLP:ondansetron hydrochloride

Concomitant use with serotonergic drugs has resulted in serotonin syndrome.

Source: NLP:oxymorphone hydrochloride

Concomitant use may result in serotonin syndrome.

Source: NLP:remifentanil hydrochloride

SSRIs co-administered with rizatriptan may cause serotonin syndrome.

Source: NLP:rizatriptan benzoate

Severe toxicity reported in patients receiving combination of selective serotonin reuptake inhibitors and selegiline hydrochloride.

Source: NLP:selegiline hydrochloride

Cases of life-threatening serotonin syndrome have been reported during combined use of SSRIs and triptans.

Source: NLP:sumatriptan succinate, camphor, menthol

Concomitant use increases risk of serotonin syndrome. Monitor patients for signs and symptoms during trazodone initiation.

Source: NLP:trazodone hydrochloride

Potential for serotonin syndrome when coadministered. Careful patient observation advised, particularly during treatment initiation and dose increases.

Source: NLP:venlafaxine hydrochloride

SSRIs concomitantly used with zolmitriptan have caused life-threatening serotonin syndrome.

Source: NLP:zolmitriptan

Concomitant use potentiates bleeding risk more than NSAID alone by affecting platelet serotonin release. Monitor for signs of bleeding.

Source: NLP:celecoxib

Concomitant use may increase risk of water intoxication with hyponatremia; requires more frequent serum sodium monitoring.

Source: NLP:desmopressin acetate

Concomitant use may increase risk of hyponatremia through SIADH. Avoid use; if unavoidable, closely monitor serum sodium concentrations.

Source: NLP:dextrose monohydrate

Monitor patients for signs of bleeding with concomitant use.

Source: NLP:diclofenac sodium, methyl salicylate

SSRIs with diclofenac may potentiate bleeding risk more than NSAID alone due to effects on platelet serotonin reuptake.

Source: NLP:diclofenac sodium, kinesiology tape

Concomitant use may potentiate bleeding risk more than NSAID alone; monitor for signs of bleeding.

Source: NLP:meloxicam

Methylphenidate may inhibit metabolism of SSRIs. Downward dose adjustments may be required and plasma concentrations should be monitored.

Source: NLP:methylphenidate

Methylphenidate may inhibit metabolism of SSRIs; downward dose adjustment may be required and plasma concentrations should be monitored.

Source: NLP:methylphenidate hydrochloride

Levels may be increased in CYP2D6-deficient individuals due to modafinil's CYP2C19 inhibition affecting ancillary elimination routes. Dose adjustment may be necessary.

Source: NLP:modafinil

Concomitant use may cause serotonin syndrome including altered mental status, autonomic instability, and neuromuscular symptoms. Monitor for emergence of serotonin syndrome.

Source: NLP:palonosetron

Concomitant use may cause serotonin syndrome including altered mental status, autonomic instability, and neuromuscular symptoms. Monitor for symptoms and discontinue palonosetron if they occur.

Source: NLP:palonosetron hydrochloride

Safety and effectiveness of concomitant use with argatroban have not been established.

Source: NLP:argatroban